You are here

Article Text

Article menu
Download PDFPDF
Original Article
Alternative Splicing-Related Factor YT521: an Independent Prognostic Factor in Endometrial Cancer
  1. Bo Zhang, MB*,†,
  2. Axel Zur Hausen, MD‡,
  3. Marzenna Orlowska-Volk, MD‡,
  4. Markus Jäger*,
  5. Herta Bettendorf, PhD*,
  6. Stefan Stamm, PhD§,
  7. Marc Hirschfeld, MSc*,
  8. Ouyang Yiqin, MSc*,
  9. Xiaowen Tong, MD†,
  10. Gerald Gitsch, MD* and
  11. Elmar Stickeler, MD*
  1. *Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg, Germany;
  2. †Department of Obstetrics and Gynecology, Tongji Hospital, Tongji University, Shanghai, China;
  3. ‡Institute of Pathology, Freiburg University Medical Center, Freiburg, Germany; and
  4. §Department of Molecular & Cellular Biochemistry BBSRB, University of Kentucky, Lexington, KY.
  1. Address correspondence and reprint requests to Elmar Stickeler, MD, Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg 79106, Germany. E-mail: elmar.stickeler{at}uniklinik-freiburg.de.

Abstract

Background: YT521 is a splicing factor involved in alternative splicing regulation of several tumor biological important genes. Two messenger RNA (mRNA) isoforms due to YT521 exon6 alternative splicing exist, with so far unknown functional consequences. Further evidence exists for a direct influence of YT521 expression in tumorigenesis because its mRNA level is changed in tumors compared with physiological tissue. We investigated the potential impact of YT521 expression on tumor biological parameters in endometrial cancer (EC).

Methods: Real-time reverse transcription-polymerase chain reaction specifically detecting YT521 exon6-retention and exon6-skipping mRNA isoforms and immunohistochemistry were performed in a cohort of 130 EC tissue samples.

Results: Whereas YT521 exon6-retention mRNA was detectable in 86 (66.2%), the exon6-skipping isoform mRNA was expressed in only 8 (6.2%) of all EC samples. On the protein level, 104 (80%) of EC samples showed nuclear expression. The mRNA levels of exon6-skipping isoform were not correlated to any of the clinicopathological parameters of EC. In contrast, YT521 exon6-retention mRNA expression was positively correlated to metastasis (R = 0.196, P = 0.026) and inversely correlated to the protein expression levels (R = −0.205, P = 0.019). In univariate analyses, higher levels of YT521 exon6-retention mRNA were correlated to a poorer progression-free survival (P = 0.003), and this is confirmed by multivariate analyses (P = 0.019). The negative YT521 protein expression was correlated to poorer overall and disease-specific survival (P = 0.036 and P = 0.034), respectively, in univariate analyses. They are also confirmed by multivariate analyses (P = 0.021 and P = 0.010, respectively).

Conclusions: We characterized for the first time in a clinical setting a new but rare exon6-skipping mRNA splicing isoform of YT521. Furthermore, we identified YT521 as a potential new independent prognostic factor for patients with EC: the lack of YT521 protein in tumor cells was highly predictive for a poor overall and disease-specific survival and independent from the histological subtypes.

  • YT521
  • Alternative splicing
  • Endometrial cancer
  • Prognostic factor

https://doi.org/10.1111/IGC.0b013e3181d66ffe

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.